Social Media and COVID-19-Perceptions and Public Deceptions of Ivermectin, Colchicine and Hydroxychloroquine: Lessons for Future Pandemics.

South Africa clinical trials colchicine hydroxychloroquine ivermectin re-purposed medicines sentiment analysis social media utilization

Journal

Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404

Informations de publication

Date de publication:
25 Mar 2022
Historique:
received: 10 02 2022
revised: 02 03 2022
accepted: 09 03 2022
entrez: 23 4 2022
pubmed: 24 4 2022
medline: 24 4 2022
Statut: epublish

Résumé

The capacity for social media to influence the utilization of re-purposed medicines to manage COVID-19, despite limited availability of safety and efficacy data, is a cause for concern within health care systems. This study sought to ascertain links between social media reports and utilization for three re-purposed medicines: hydroxychloroquine (HCQ), ivermectin and colchicine. A combined retrospective analysis of social media posts for these three re-purposed medicines was undertaken, along with utilization and clinical trials data, in South Africa, between January 2020 and June 2021. In total, 77,257 posts were collected across key social media platforms, of which 6884 were relevant. Ivermectin had the highest number of posts (55%) followed by HCQ (44%). The spike in ivermectin use was closely correlated to social media posts. Similarly, regarding chloroquine (as HCQ is not available in South Africa), social media interest was enhanced by local politicians. Sentiment analysis revealed that posts regarding the effectiveness of these repurposed medicines were positive. This was different for colchicine, which contributed only a small number of mentions (1%). Of concern is that the majority of reporters in social media (85%) were unidentifiable. This study provides evidence of social media as a driver of re-purposed medicines. Healthcare professionals have a key role in providing evidence-based advice especially with unidentifiable posts.

Identifiants

pubmed: 35453198
pii: antibiotics11040445
doi: 10.3390/antibiotics11040445
pmc: PMC9031711
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : South African Medical Council
ID : No Number

Références

BMJ. 2004 Jul 3;329(7456):47-50
pubmed: 15231628
Am J Trop Med Hyg. 2020 Jun;102(6):1184-1188
pubmed: 32323646
Front Pharmacol. 2021 Jan 14;11:588106
pubmed: 33628173
S Afr Med J. 2021 Aug 17;111(10):934-937
pubmed: 34949284
BMJ. 2021 Mar 1;372:n526
pubmed: 33649077
Front Pharmacol. 2021 May 06;12:584940
pubmed: 34025393
Lancet Digit Health. 2021 Mar;3(3):e175-e194
pubmed: 33518503
Health Promot Perspect. 2020 Nov 07;10(4):290-291
pubmed: 33312921
PLoS One. 2021 Dec 28;16(12):e0261358
pubmed: 34962939
Int Braz J Urol. 2020 Jul;46(suppl.1):120-124
pubmed: 32550706
Lancet. 2020 May 30;395(10238):1689-1690
pubmed: 32422123
N Engl J Med. 2021 Feb 11;384(6):497-511
pubmed: 33264556
JAMA. 2020 Dec 1;324(21):2161-2162
pubmed: 33165507
Clin Pharmacol. 2020 Aug 17;12:115-121
pubmed: 32904117
MMWR Morb Mortal Wkly Rep. 2020 Mar 20;69(11):307-311
pubmed: 32191691
Z Gesundh Wiss. 2021 Oct 09;:1-10
pubmed: 34660175
Ther Clin Risk Manag. 2021 Apr 28;17:371-387
pubmed: 33953559
Int J Antimicrob Agents. 2020 Jul;56(1):106056
pubmed: 32674929
BMJ. 2020 Oct 19;371:m4057
pubmed: 33077424
Xenobiotica. 2021 Jun;51(6):643-656
pubmed: 33845715
Ther Adv Infect Dis. 2020 Aug 4;7:2049936120947517
pubmed: 32821381
Acad Emerg Med. 2020 Jul;27(7):640-641
pubmed: 32474977
Curr Med Res Opin. 2020 Feb;36(2):301-327
pubmed: 31794332
Cochrane Database Syst Rev. 2020 Sep 15;9:CD013574
pubmed: 33959956
Malays J Med Sci. 2020 Jul;27(4):154-158
pubmed: 32863755
Eur J Pharmacol. 2021 May 5;898:173977
pubmed: 33639193
Curr Pharmacol Rep. 2020;6(4):137-145
pubmed: 32837853
Infect Drug Resist. 2020 Dec 29;13:4673-4695
pubmed: 33402839
Expert Rev Clin Pharmacol. 2021 Jan;14(1):95-103
pubmed: 33252992
Cureus. 2020 Sep 14;12(9):e10453
pubmed: 33072461
Cardiol Res. 2020 Oct;11(5):267-268
pubmed: 32849959
Lancet Respir Med. 2021 Dec;9(12):1419-1426
pubmed: 34672950
Crit Care Explor. 2021 Nov 02;3(11):e0566
pubmed: 34746796
Lancet Respir Med. 2021 Aug;9(8):924-932
pubmed: 34051877
Int J Antimicrob Agents. 2020 Jul;56(1):106063
pubmed: 32674928
BMJ. 2021 Apr 1;373:n747
pubmed: 33795225
N Engl J Med. 2020 Nov 19;383(21):2030-2040
pubmed: 33031652
Antibiotics (Basel). 2022 Jan 14;11(1):
pubmed: 35052982
Med Mal Infect. 2020 Jun;50(4):384
pubmed: 32240719
Int J Infect Dis. 2017 Nov;64:100-106
pubmed: 28893672
Antiviral Res. 2020 Jun;178:104787
pubmed: 32251768
Virusdisease. 2020 Jun;31(2):161-173
pubmed: 32656310
J Med Internet Res. 2020 Oct 9;22(10):e19684
pubmed: 33006940
Front Public Health. 2020 Dec 14;8:585832
pubmed: 33381485
J Res Pharm Pract. 2017 Apr-Jun;6(2):120-125
pubmed: 28616436
Res Social Adm Pharm. 2021 Jan;17(1):2032-2035
pubmed: 32245691
Front Immunol. 2019 Mar 28;10:549
pubmed: 30984169
Telemat Inform. 2021 Jan;56:101475
pubmed: 34887612
Clin Infect Dis. 2022 Mar 23;74(6):1022-1029
pubmed: 34181716
J Med Internet Res. 2015 Jun 10;17(6):e144
pubmed: 26063290
PLoS Med. 2021 Jul 1;18(7):e1003682
pubmed: 34197449
Hum Vaccin Immunother. 2022 Dec 31;18(1):1950504
pubmed: 34325612
Lancet. 2020 Oct 24;396(10259):1345-1352
pubmed: 33031764
Front Pharmacol. 2017 Aug 23;8:497
pubmed: 28878667
Res Social Adm Pharm. 2021 Jan;17(1):1964-1966
pubmed: 32317154
Front Pharmacol. 2020 Sep 11;11:1205
pubmed: 33071775
J Res Pharm Pract. 2021 May 13;10(1):17-22
pubmed: 34295848
BMJ Evid Based Med. 2022 Jun;27(3):156-158
pubmed: 33888547
Glob Public Health. 2020 Dec;15(12):1753-1766
pubmed: 33019916
Sci Transl Med. 2021 Sep 22;13(612):eabd5524
pubmed: 34550729
BMJ. 2020 Apr 8;369:m1432
pubmed: 32269046
BMC Public Health. 2021 May 29;21(1):1015
pubmed: 34051769
Healthcare (Basel). 2021 Dec 13;9(12):
pubmed: 34946448
J Med Internet Res. 2020 Aug 19;22(8):e19996
pubmed: 32750004
Braz J Infect Dis. 2020 Jul - Aug;24(4):369-371
pubmed: 32615072
Int Immunopharmacol. 2021 Jul;96:107723
pubmed: 34162130
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
BMJ. 2020 Apr 6;369:m1373
pubmed: 32253180
Health Econ. 2019 Nov;28(11):1377-1382
pubmed: 31429153

Auteurs

Natalie Schellack (N)

Department of Pharmacology, Faculty of Health Sciences, University of Pretoria, Pretoria 0084, South Africa.

Morné Strydom (M)

Department of Pharmacology, Faculty of Health Sciences, University of Pretoria, Pretoria 0084, South Africa.

Michael S Pepper (MS)

Institute for Cellular and Molecular Medicine, Department of Immunology and SAMRC Extramural Unit for Stem Cell Research and Therapy, Faculty of Health Sciences, University of Pretoria, Pretoria 0084, South Africa.

Candice L Herd (CL)

Institute for Cellular and Molecular Medicine, Department of Immunology and SAMRC Extramural Unit for Stem Cell Research and Therapy, Faculty of Health Sciences, University of Pretoria, Pretoria 0084, South Africa.

Candice Laverne Hendricks (CL)

Institute for Cellular and Molecular Medicine, Department of Immunology and SAMRC Extramural Unit for Stem Cell Research and Therapy, Faculty of Health Sciences, University of Pretoria, Pretoria 0084, South Africa.

Elmien Bronkhorst (E)

School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria 0084, South Africa.

Johanna C Meyer (JC)

School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria 0084, South Africa.

Neelaveni Padayachee (N)

Department of Pharmacy and Pharmacology, Faculty of Health Sciences, School of Therapeutic Sciences, University of Witwatersrand, Johannesburg 2050, South Africa.

Varsha Bangalee (V)

Discipline of Pharmaceutical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban 4041, South Africa.

Ilse Truter (I)

Drug Utilization Research Unit (DURU), Department of Pharmacy, Nelson Mandela University, Port Elizabeth 6031, South Africa.

Andrea Antonio Ellero (AA)

Department of Pharmacology, Faculty of Health Sciences, University of Pretoria, Pretoria 0084, South Africa.
Centre for Neuroendocrinology (CNE), Department of Immunology, University of Pretoria, Pretoria 0084, South Africa.

Thulisa Myaka (T)

Department of Pharmacology, Faculty of Health Sciences, University of Pretoria, Pretoria 0084, South Africa.

Elysha Naidoo (E)

Department of Pharmacology, Faculty of Health Sciences, University of Pretoria, Pretoria 0084, South Africa.

Brian Godman (B)

School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria 0084, South Africa.
Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK.
Centre of Medical and Bio-Allied Health Sciences Research, Ajman University, Ajman P.O. Box 346, United Arab Emirates.

Classifications MeSH